Since the middle of the month on November 15th, we've seen a lot of choppy action in this market. The S&P 500 is up 0.24% since November 15th, while the Nasdaq 100 (the largest stocks in the Nasdaq Composite) is up 0.14%. Within the major indices, though, we've seen a lot of stocks go up and a lot of stocks go down, effectively cancelling each other out to result in a sideways market.
Year-to-date through November 15th, the average stock in the Nasdaq 100 was up a whopping 39.90%. As shown in the chart below, the average stock in the Nasdaq 100 is down 0.41% since then, but the divergence in sector performance has been stark. Since 11/15, the average Health Care stock (mostly Biotechs) in the Nasdaq 100 has surged 3.19%. The average Technology stock, however, has averaged a decline of 1.22%. If you're overweight Tech and underweight Health Care, chances are you've been underperforming the market since the middle of the month.
Below is a look at the 10 best and 10 worst performing Nasdaq 100 stocks since November 15th. In a flat market, we've seen some pretty sharp moves on both the upside and downside. Biotech stocks like Biogen (BIIB), Celgene (CELG), Vertex (VRTX), Gilead Sciences (GILD) and Regeneron (REGN) are all up more than 5%, while Tesla (TSLA) and other Tech stocks like Facebook (FB), eBay (EBAY), SanDisk (SNDK) and Sirius (SIRI) are all down more than 5%. There has been a lot of pain and a lot of gain so far in the second half of November.